US20080261948A1 - Ligands for G-Protein Coupled Receptors - Google Patents

Ligands for G-Protein Coupled Receptors Download PDF

Info

Publication number
US20080261948A1
US20080261948A1 US11/815,928 US81592806A US2008261948A1 US 20080261948 A1 US20080261948 A1 US 20080261948A1 US 81592806 A US81592806 A US 81592806A US 2008261948 A1 US2008261948 A1 US 2008261948A1
Authority
US
United States
Prior art keywords
receptors
group
alkyl
compound
radical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/815,928
Other languages
English (en)
Inventor
David J. Grainger
David John Fox
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Huntsman Textile Effects Germany GmbH
Cambridge Enterprise Ltd
Original Assignee
Huntsman Textile Effects Germany GmbH
Cambridge Enterprise Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Huntsman Textile Effects Germany GmbH, Cambridge Enterprise Ltd filed Critical Huntsman Textile Effects Germany GmbH
Assigned to HUNTSMAN TEXTILE EFFECTS (GERMANY) GMBH reassignment HUNTSMAN TEXTILE EFFECTS (GERMANY) GMBH ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ANGELE, THEODOR, CHROBACZEK, HARALD, DAUTH, JOCHEN
Publication of US20080261948A1 publication Critical patent/US20080261948A1/en
Assigned to CAMBRIDGE ENTERPRISE LIMITED reassignment CAMBRIDGE ENTERPRISE LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: FOX, DAVID JOHN, GRAINGER, DAVID J.
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/06—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof

Definitions

  • the invention relates to the generation of a library of compounds enriched in agonists and antagonists for members of the G-protein coupled class of receptors (GPCRs).
  • GPCRs G-protein coupled class of receptors
  • GPCR G-protein coupled receptor
  • the activated (or R*) conformation of the receptor is then able to interact with a member of the G-protein family.
  • the G-proteins are a large family of trimeric intracellular proteins which bind guanine nucleotides.
  • the G-protein exchanges a bound guanosine diphosphate (GDP) for a guanosine triphosphate (GTP).
  • GDP bound guanosine diphosphate
  • GTP guanosine triphosphate
  • the G-protein trimer dissociates, yielding a free G ⁇ subunit, and a ⁇ dimer. Both the G ⁇ and ⁇ subunits can then participate in further signalling cascades.
  • the G ⁇ subunit can activate the adenylate cyclase (AC) enzyme, which generates cyclic adenosine monophospate (cAMP) from adenosine triphosphate.
  • AC adenylate cyclase
  • cAMP cyclic adenosine monophospate
  • the ⁇ subunit can activate members of the PI-3-kinase family of enzymes. Ultimately, these signals can result in modulation of almost every aspect of cell behaviour, from contraction to motility, metabolism to further signalling.
  • the signal once activated, is then slowly turned off by a number of mechanisms.
  • the GTP associated with the G ⁇ subunit is hydrolysed back to GDP, resulting in the reassociation of the G ⁇ and ⁇ subunits to form the inactive trimeric GDP-bound G-protein.
  • the GPCR itself also becomes phosphorylated on the intracellular C-terminus, preventing further interaction with G-proteins. Eventually, the bound ligand may also dissociate.
  • This generic signalling pathway is so central and ubiquitous in mammalian physiology that as many as 40% of licensed pharmaceuticals have a GPCR among their molecular targets.
  • bacteria have evolved to target G-protein signalling in order to disrupt host physiology and immunity: Vibrio cholerae (the organism responsible for cholera), for example, makes a protein known as cholera toxin which irreversibly inhibits the G ⁇ subunit of a widely distributed G-protein called G s .
  • G s the organism responsible for Whooping Cough
  • Bordetella pertussis makes a protein known as Pertussis toxin which has a similar effect on a different G-protein, G i .
  • Another major problem with such “negative screening” paradigms where you detect the ability of the test library to block binding of a labelled ligand is that most of the leads identified are receptor antagonists. Few of the leads have any agonist activity (as expected—agonist activity requires the ability to bind to and then convert the receptor to the activated conformation, whereas antagonist actively merely requires the ability to bind to the receptor or ligand in such a way as to prevent their interactions) and generating analogs of the initial antagonist leads to convert them to agonists is a “hit and miss” affair with very low success rates.
  • One approach to circumventing this problem would be to replace the random compound library with a library of molecular structures preselected to contain a high proportion of GPCR binding compounds.
  • a library would also ideally include both agonists and antagonists in similar proportion so that either could be readily located.
  • the basic molecular structures used in the library would be non-toxic.
  • the requirements for the generation of said libraries are: (i) the identification of the molecular motif necessary for binding to GPCRs (ii) a skeleton incorporating this molecular motif so as to retain GPCR binding, but also providing low intrinsic toxicity and good stability, pharmacokinetics and/or pharmacodynamics (iii) a facile synthetic route to generate diverse substitution of the skeleton.
  • the present invention is based on the ideal substrate below:
  • the skeletons which are provided have been designed using the wide availability of ⁇ -amino acids as starting materials in order to generate the diversity of substitution (see, for example, Unnatural Amino Acids: Tools for Drug Discovery; Sigma-Aldrich ChemFiles Vol 4 No. 6).
  • Each of the skeletons is synthesised from the combination of two ⁇ -amino acids.
  • the first may be selected from cysteine, penicillamine or 3-aminoalanine. Any amino acid is then paired with the first amino acid to generate the requisite diversity.
  • the invention provides compounds and salts thereof of general formula (I), representing the synthetic product of reactions using cysteine and a second amino acid as the starting materials:
  • X is —CO—(Y) k -(Z) n or SO 2 —(Y) k -(Z) n ;
  • k 0 or 1
  • Y is a cycloalkyl or polycyloalkyl group (such as an adamantyl, adamantanemethyl, bicyclooctyl, cyclohexyl, cyclopropyl group);
  • Y is a cycloalkenyl or polycycloalkenyl group
  • each Z is independently selected from hydrogen or an alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, alkylamino, alkylaminoalkyl, alkylaminodialkyl, charged alkylaminotrialkyl or charged alkylcarboxylate radical of 1 to 20 carbon atoms;
  • each Z is independently selected from fluoro, chloro, bromo, iodo, hydroxy, oxyalkyl, amino, aminoalkyl, aminodialkyl, charged aminotrialkyl, or carboxylate radical;
  • n is any integer from 1 to m, where m is the maximum number of substitutions permissible on the cyclo-group Y.
  • Z may be selected from a peptido radical, for example having from 1 to 4 peptidic moieties linked together by peptide bonds (for example a peptido radical of 1 to 4 amino acid residues)
  • R 3 and R 4 represent the diverse substitutions which, together with Z, distinguish one library element from another.
  • This class of compounds 6-acylamino-[1,4]thiazepan-5-ones, are described as “Thiofoxins”.
  • the key structural features of the molecules are the lactam amide in a ring system, with an amino group attached to the carbon atom next to the lactam carbonyl group (the 6-position, termed the ⁇ -carbon), and sulfur at the 1 position and R 3 and R 4 (variable) at the 3 and 2 positions of the lactam ring, respectively.
  • the invention also provides compounds and salts thereof of general formula (II), representing the synthetic product of reactions using penicillamine and a second amino acid as the starting materials:
  • X is —CO—(Y) k -(Z) n or SO 2 —(Y) k -(Z) n ;
  • k 0 or 1
  • Y is a cycloalkyl or polycyloalkyl group (such as an adamantyl, adamantanemethyl, bicyclooctyl, cyclohexyl, cyclopropyl group);
  • Y is a cycloalkenyl or polycycloalkenyl group
  • each Z is independently selected from hydrogen or an alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, alkylamino, alkylaminoalkyl, alkylaminodialkyl, charged alkylaminotrialkyl or charged alkylcarboxylate radical of 1 to 20 carbon atoms;
  • each Z is independently selected from fluoro, chloro, bromo, iodo, hydroxy, oxyalkyl, amino, aminoalkyl, aminodialkyl, charged aminotrialkyl, or carboxylate radical;
  • Z may be selected from a peptido radical, for example having from 1 to 4 peptidic moieties linked together by peptide bonds (for example a peptido radical of 1 to 4 amino acid residues)
  • R 3 and R 4 represent the diverse substitutions which, together with Z, distinguish one library element from another.
  • R 3 and R 4 may be independently selected as any substituent group, except that R 3 may not be —COOH, —COOR′, —COSR′, or —CONR′R′′ where R′ and R′′ independently are any substituent and either or both of R′ and R′′ can be H.
  • This class of compounds 6-acylamino-7,7-dimethyl[1,4]thiazepan-5-ones, are described as “Dimethylthiofoxins”.
  • the key structural features of the molecules are the lactam amide in a ring system, with an amino group attached to the carbon atom next to the lactam carbonyl group (the 6-position, termed the ⁇ -carbon), and sulfur at the 1 position and R 3 and R 4 (variable) at the 3 and 2 positions of the lactam ring, respectively.
  • the invention also provides compounds and salts thereof of general formula (III), representing the synthetic product of reactions using 3-aminoalanine and a second amino acid as the starting materials:
  • X is —CO—(Y) k -(Z) n or SO 2 —(Y) k -(Z) n ;
  • k 0 or 1
  • Y is a cycloalkyl or polycyloalkyl group (such as an adamantyl, adamantanemethyl, bicyclooctyl, cyclohexyl, cyclopropyl group);
  • Y is a cycloalkenyl or polycycloalkenyl group
  • each Z is independently selected from hydrogen or an alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, alkylamino, alkylaminoalkyl, alkylaminodialkyl, charged alkylaminotrialkyl or charged alkylcarboxylate radical of 1 to 20 carbon atoms;
  • each Z is independently selected from fluoro, chloro, bromo, iodo, hydroxy, oxyalkyl, amino, aminoalkyl, aminodialkyl, charged aminotrialkyl, or carboxylate radical;
  • n is any integer from 1 to m, where m is the maximum number of substitutions permissible on the cyclo-group Y.
  • Z may be selected from a peptido radical, for example having from 1 to 4 peptidic moieties linked together by peptide bonds (for example a peptido radical of 1 to 4 amino acid residues)
  • R 2 , R 3 and R 4 represent the diverse substitutions which, together with Z, distinguish one library element from another.
  • This class of compounds 6-acylamino-[1,4]diazepan-5-ones, are described as “Azafoxins”.
  • the key structural features of the molecules are the lactam amide in a ring system, with an amino group attached to the carbon atom next to the lactam carbonyl group (the 6-position, termed the ⁇ -carbon), and nitrogen at the 1 position and R 3 and R 4 (variable) at the 3 and 2 positions of the lactam ring, respectively.
  • further diversity can be generated by substitution with R 2 (variable) at the N1 position.
  • the invention also provides compounds and salts thereof of general formula (IV), representing an alternative synthetic product of reactions using 3-aminoalanine and a second amino acid as the starting materials:
  • X is —CO—(Y) k -(Z) n or SO 2 —(Y) k -(Z) n ;
  • k 0 or 1
  • Y is a cycloalkyl or polycyloalkyl group (such as an adamantyl, adamantanemethyl, bicyclooctyl, cyclohexyl, cyclopropyl group);
  • Y is a cycloalkenyl or polycycloalkenyl group
  • each Z is independently selected from hydrogen or an alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl, alkylamino, alkylaminoalkyl, alkylaminodialkyl, charged alkylaminotrialkyl or charged alkylcarboxylate radical of 1 to 20 carbon atoms;
  • each Z is independently selected from fluoro, chloro, bromo, iodo, hydroxy, oxyalkyl, amino, aminoalkyl, aminodialkyl, charged aminotrialkyl, or carboxylate radical;
  • n is any integer from 1 to m, where m is the maximum number of substitutions permissible on the cyclo-group Y.
  • Z may be selected from a peptido radical, for example having from 1 to 4 peptidic moieties linked together by peptide bonds (for example a peptido radical of 1 to 4 amino acid residues)
  • R 2 and R 3 represent the diverse substitutions which, together with Z, distinguish one library element from another.
  • This class of compounds 6-acylamino-[1,4]diazepan-2,5-diones, are described as “Amidofoxins”.
  • the key structural features of the molecules are the lactam amide in a ring system, with an amino group attached to the carbon atom next to the lactam carbonyl group (the 6-position, termed the ⁇ -carbon), nitrogen at the 1 position, a carbonyl group at the 2 position with R 3 (variable) at the 3 position of the lactam ring.
  • R 3 variable
  • further diversity can be generated by substitution with R 2 (variable) at the N1 position.
  • the ⁇ -carbon of these Thiofoxins, Dimethylthiofoxins, Azafoxins, and Amidofoxins is asymmetric and consequently, the compounds according to the present invention have two possible enantiomeric forms, that is, the “R” and “S” configurations.
  • the present invention encompasses the two enantiomeric forms and all combinations of these forms, including the racemic “RS” mixtures. With a view to simplicity, when no specific configuration is shown in the structural formulae, it should be understood that the two enantiomeric forms and their mixtures are represented.
  • the compounds of general formulae (I), (II), (III) and (IV) are all N-substituted on the exocyclic amine group.
  • the N-substitutent is either a carbon amide or a sulfonamide.
  • the geometry of the carbon atom next to the carbonyl of the carbon amide or the sulfoyl group of the sulfonamide (the “key” carbon) may be important for the bioactivity of the molecule.
  • the nature of this N-substituent may be such that the ring or rings of Y constrain the bond angles at the “key”-carbon to be essentially tetrahedral (i.e. sp3 hybrid bonds).
  • any substituent Z may be a substituent at any permissible position on the ring or rings of the cyclo-group Y.
  • the invention includes compounds in which the “key carbon” is both part of the cyclo group and is itself substituted.
  • One major advantage of the compounds of the invention is that the diverse library elements may be readily synthesised from widely available starting materials.
  • Thiofoxins, Dimethylthiofoxins, Azafoxins and Amidofoxins each represent a diverse class of compounds (with diversity at the Z, R 2 (if applicable), R 3 and (if applicable) R 4 positions) which can be readily synthesised from two different ⁇ -amino acids.
  • ⁇ -amino acids represent an ideal starting material for diversity-oriented synthesis since a wide range of ⁇ -amino acids (differing only in the nature of the R 3 substituent) are known, and are commercially available.
  • ⁇ -amino acids are readily reduced to yield ⁇ -amino alcohols (using protecting groups to retain the structure of the R 3 moiety if required).
  • the diverse ⁇ -amino alcohols are then coupled to cysteine to yield “Thiofoxamines”, to penicillamine to yield “Dimethylthiofoxamines”, or to 3-aminoalanine to yield “Azafoxamines.
  • These ⁇ -aminolactams can then be coupled to an appropriate acyl side chain by conventional amide coupling reactions (again protecting the R 3 substituent if required), yielding Thiofoxins, Dimethylthiofoxins or Azafoxins respectively.
  • Amidofoxins are generated by reacting the ⁇ -amino-acid (without first reducing it to the ⁇ -aminoalcohol) with 3-aminoalanine. It will be noticed that Amidofoxins are 7-membered ring analogs of the well-studied diketopiperazines generated from ⁇ -amino acid dimers, but generated from a dimer of a ⁇ -amino acid (3-aminoalanine) and an ⁇ -amino acid.
  • the resulting Thiofoxins, Dimethylthiofoxins, Azafoxins and Amidofoxins have the same range of R 3 substituents as the original collection of available ⁇ -amino acids.
  • general synthetic routes for generating ⁇ -amino acids are well known in the art (for example, see R. M. Williams, Synthesis of Optically Active a-Amino Acids (Pergamon, New York) 1989), allowing even greater diversity to be generated as required.
  • variable 2-substitution allow the introduction of additional diversity as a variable R 4 group at the 2-position of the ring in Thiofoxins, Dimethylthiofoxins and Azafoxins.
  • a prior reductive alkylation of the 3-aminoalanine moiety allows introduction of diversity at the N1 position in Azafoxins or Amidofoxins (the variable R 2 group).
  • a particular feature of the present invention is the facile stereocontrol of the synthesis.
  • the exemplified routes use cheap and readily available L-cysteine, L-penicillamine and L-3-aminoalanine to couple with diverse ⁇ -amino alcohols (or directly with ⁇ -amino acids in the case of Amidofoxins). This results in a diverse series of ⁇ -aminolactams which are of the (S)-configuration.
  • D-cysteine, D-penicillamine and D-3-aminoalanine are also readily available, and can be coupled with the same diverse ⁇ -amino alcohols (or ⁇ -amino acids) to yield ⁇ -aminolactams of the (R)-configuration.
  • racemic mixtures of one or both starting materials may be selected, yielding mixed stereoisomers of the Thiofoxamine, Dimethylthiofoxamine, Azafoxamine and/or Amidofoxamine and hence Thiofoxin, Dimethylthiofoxin, Azafoxin, and/or Amidofoxin products.
  • the last step should introduce the greatest diversity into the library. Since diversity may be introduced at several steps in the synthesis of the compounds of the invention (with variable Z, R 2 (for Azafoxins and Amidofoxins).
  • R 3 and R 4 for Thiofoxins, Dimethylthiofoxins and Azafoxins
  • it is possible to introduce diversity equally at each step for example to have 8 different Z groups, R 2 groups and R 3 groups in an Amidofoxin library, thereby yielding 512 compounds
  • to introduce greater diversity at one of the steps for example to have 2 different Z and R 2 groups, but 128 different R 3 groups in an Amidofoxin library, thereby yielding 512 compounds.
  • this step is advantageous to have this step as late as possible in the synthetic route.
  • One advantage of the invention provided here is that the synthetic routes are well suited to changes in the order of the reaction steps.
  • synthesis of library elements may be carried out using parallel synthesis methods well known in the art.
  • the synthesis may be performed using resins or other solid-phase supports to simplify the introduction of diversity and to facilitate the purification, or partial purification, of the library element products.
  • Application of such solid phase, or other parallel synthesis, methodologies, whether manual, semi-automated or automated, to generate a library of Thiofoxins, Dimethylthiofoxins, Azafoxins or Amidofoxins falls under the scope of the present invention.
  • the invention also provides pharmaceutical compositions comprising, as active ingredient, a compound of general formula (I), (II), (III) or (IV), or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable excipient and/or carrier.
  • salt in particular the addition salts of inorganic acids such as hydrochloride, hydrobromide, hydroiodide, sulphate, phosphate, diphosphate and nitrate or of organic acids such as acetate, maleate, fumarate, tartrate, succinate, citrate, lactate, methanesulphonate, p-toluenesulphonate, palmoate and stearate.
  • inorganic acids such as hydrochloride, hydrobromide, hydroiodide, sulphate, phosphate, diphosphate and nitrate
  • organic acids such as acetate, maleate, fumarate, tartrate, succinate, citrate, lactate, methanesulphonate, p-toluenesulphonate, palmoate and stearate.
  • bases such as sodium or potassium hydroxide.
  • Salt selection for basic drugs Int. J. Pharm . (1986), 33, 201-217.
  • the pharmaceutical composition can be in the form of a solid, for example powders, granules, tablets, gelatin capsules, liposomes or suppositories.
  • Appropriate solid supports can be, for example, calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, methyl cellulose, sodium carboxymethyl cellulose, polyvinylpyrrolidine and wax.
  • Other appropriate pharmaceutically acceptable excipients and/or carriers will be known to those skilled in the art.
  • compositions according to the invention can also be presented in liquid form, for example, solutions, emulsions, suspensions or syrups.
  • Appropriate liquid supports can be, for example, water, organic solvents such as glycerol or glycols, as well as their mixtures, in varying proportions, in water.
  • the invention may also provide the use of a compound of general formula (I), (II), (III) and/or (IV), or a pharmaceutically acceptable salt thereof, for the preparation of a medicament intended to modulate the activity of one or more members of the G-protein coupled receptor (GPCR) class.
  • GPCR G-protein coupled receptor
  • the invention provides compounds, compositions and uses of the compounds of general formula (I), (II), (III) and (IV) or their pharmaceutically acceptable salts, wherein the R 1 radical has a “key” carbon which is di-substituted with the same or different groups selected from: alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, alkynl and alkylamino radicals.
  • the invention provides compounds, compositions and uses wherein the “key” carbon is chiral.
  • the invention provides compounds, compositions and uses wherein the “key” carbon has sp3 hybridised bonds.
  • the invention provides compounds, compositions and uses wherein the “key” carbon has essentially tetrahedral bond angles.
  • the compounds of general formula (I), (II), (III) or (IV) when used in the invention, or their salts, may be such that the ring or rings of Y constrain the bond angles at the “key” carbon to be essentially tetrahedral (i.e. sp3 hybrid bonds).
  • the invention also provides the sulfonamide analogues of the exemplified compounds: i.e. the sulfonyl- ⁇ -aminolactam-derived Thiofoxin, Dimethylthiofoxin, Azafoxin or Amidofoxin equivalents of the compounds of Formula (I), (II), (III) and (IV) respectively.
  • the invention includes compounds, compositions and uses thereof as defined, wherein the compound is in hydrated or solvated form.
  • the amide and sulfonamide Thiofoxins, Dimethylthiofoxins, Azafoxins and Amidofoxins described here are likely to be functional GPCR agonists and antagonists.
  • the core consisting of the “key” carbon, the carbonyl or sulfonyl group, the ⁇ -amino group and the Thiofoxin, Dimethylthiofoxin, Azafoxin or Amidofoxin ring represents an example of a GPCR ligand.
  • the invention also provides for a library consisting of two or more members of the class of compounds designated by general formula (I), (II), (III) and/or (IV), such that the library may be screened to identify a molecule with a particular desirable set of properties with regard to modulating signalling at one (or more) GCPRs.
  • the said library would then be screened for antagonist or agonist activity at the said GPCR(s) using methods well known in the art.
  • the library may be screened for the ability of individual library elements to block the binding of a radiolabelled GPCR ligand to a membrane preparation containing recombinant or purified GPCR.
  • the library may be screened for the ability of individual library elements to stimulate cAMP production in cells expressing a recombinant GPCR.
  • Any Thiofoxin, Dimethylthiofoxin, Azafoxin or Amidofoxin compound according to the invention which exhibits desirable properties can be used as a template for synthesis of the analogous “Carbofoxin” (which has a carbon group rather than sulfur at the 1 position in Thiofoxins or Dimethylthiofoxins, or nitrogen at the 1 position in Azafoxins or Amidofoxins), for example by using ring-closing metathesis synthetic routes which are well known in the art (such as Truka, T. M.; Grubbs, R. H. Acc. Chem. Res. 2001, 34, 18).
  • Suitable ring closing-metathesis routes have also been exemplified which could be used to synthesise “Carbofoxin” analogs of Azafoxins or Amidofoxins where the N at position 1 is substituted (i.e. R 2 ⁇ H), such as the method of Del Valle R. R. & Goodman M. J. Org. Chem. 2004, 69.8946.
  • Such “Carbofoxin” compounds are expected to be useful GPCR agonists or antagonists.
  • the invention also provides a method of treatment, amelioration or prophylaxis of the symptoms of disease or condition selected from the group consisting of hypertension, atherosclerosis, asthma, obesity, neurodegenerative disorders, autoimmune disorders or psychopathic disorders by the administration to a patient of an effective amount of a compound, composition or medicament of the invention designed to modulate GPCR activity.
  • compositions comprising as active ingredient a compound
  • this terminology is intended to cover both compositions in which other active ingredients may be present and also compositions which consist only of one active ingredient as defined.
  • peptidic moieties used herein is intended to include the following 20 naturally-occurring proteogenic amino acid residues:
  • SYMBOL MEANING Ala Alanine Cys Cysteine Asp Aspartic Acid Glu Glutamic Acid Phe Phenylalanine Gly Glycine His Histidine Ile Isoleucine Lys Lysine Leu Leucine Met Methionine Asn Asparagine Pro Proline Gln Glutamine Arg Arginine Ser Serine Thr Threonine Val Valine Trp Tryptophan Tyr Tyrosine
  • protecting groups are used.
  • the functional properties of the required protecting groups are specified (that is, in certain steps it is required that two different protecting groups are used which are removed by different reaction condtions—i.e. orthogonal protecting groups), but the molecular composition is not specified.
  • Any suitable protecting group well known in the art may be substituted. Consequently, variable elements of such protecting groups are designated R 5 , R 6 , R 7 and/or R 8 in the following examples.
  • the protecting groups (and hence the R 5 , R 6 , R 7 and R 8 substituents) are not themselves part of the products falling under the scope of the invention.
  • the Thiofoxins are products of the coupling of cysteine with a ⁇ -amino alcohol (possibly derived from the reduction of an ⁇ -amino acid).
  • the R 1 group is introduced, then the R 3 /R 4 group, and then the compounds are cyclised. Such a route would be optimal if greater diversity was to be introduced at R 3 /R 4 than R 1 .
  • the R 1 -containing acyl (or sulfonamide) substituent is introduced by an appropriate amide coupling route, several of which are well known in the art, e.g. DCC coupling.
  • one or more ⁇ -amino alcohols are obtained (e.g. ephedrine) or synthesised from ⁇ -amino acids,
  • the amino group is protected (e.g. by addition of a Boc group, or by obtaining the appropriately protected ⁇ -amino acid from a commercial supplier).
  • Boc-protected amino acids are converted to amino alcohols by reduction, and the Boc-protected ⁇ -amino alcohol (whether purchased or obtained by reduction of an amino acid) is modified so as to provide a suitable leaving group to allow alkylation of the side-chain heteroatom (in this case, the sulfur of cysteine), for example the amino-protected ⁇ -amino alcohol could be mesylated.
  • suitable methods for reduction and mesylation exist, and are well known in the art (e.g. Synthesis (1992) 1359 or Synthesis (1996) 1223).
  • the acylcysteine is alklylated at the sulfur centre using any of several appropriate methods which are well known in the art (e.g. J Med Chem. (1987) 30:1984).
  • Each ⁇ -amino alcohol is reacted separated with an appropriate acylcysteine to yield individual library elements with variable R 1 , R 2 and R 3 depending on the selection of acylcysteines and ⁇ -amino alcohols available.
  • the nitrogen introduced at this step is hereafter termed the ⁇ -amine group.
  • the S-alkyl acylcysteines are cyclised.
  • the ⁇ -amine is selectively deprotected and condensed with the carboxy ester (or after selective hydrolysis the corresponding carboxylic acid) to form a seven-membered ring, yielding Thiofoxin library elements. Similar methods are well known in the art (e.g. J. Med. Chem (1987) 30:1984).
  • cysteine is selectively protected at the ⁇ -amine, and is then alkylated on S with an N-protected ⁇ -amino-alcohol in which the alcohol has been activated to form a leaving group suitable for nucleophilic substitution with inversion of stereochemistry at carbon.
  • the introduced nitrogen is here-on called the ⁇ -amine group (for similar see Tetrahedron, 1999, 55, 10155).
  • One or more ⁇ -amino alcohols suitable for this alkylation are obtained (e.g. ephedrine) or synthesised from ⁇ -amino acids, In each case, the amino agroup is protected (e.g. by addition of a Boc group, or by obtaining the appropriately protected ⁇ -amino acid from a commercial supplier). Boc-protected amino acids are converted to amino alcohols by reduction, and the Boc-protected ⁇ -amino alcohol (whether purchased or obtained by reduction of an amino acid) is mesylated.
  • Several suitable methods for reduction and mesylation exist, and are well known in the art (e.g. Synthesis (1992) 1359 or Synthesis (1996) 1223).
  • the ⁇ -amine is selectively deprotected and condensed with the carboxy ester (or after selective hydrolysis the corresponding carboxylic acid) to form a seven-membered ring (according to J. Med. Chem., 1987, 30, 1984).
  • the ⁇ -amine is selectively deprotected and acylated as required to introduce diversity at the R 1 position, using an appropriate peptide coupling reagent, several of which are well known in the art.
  • Compound (V) is a histamine H2 or gastrin receptor ligand (depending on the nature of R and X) described in Bioorg. Med. Chem (1997) 5:1411 and compound (VI) is a Neuropeptide Y receptor ligand described in Bioorg. Med. Chem, (1999) 7:1703.
  • compound (V) is a histamine H2 or gastrin receptor ligand (depending on the nature of R and X) described in Bioorg. Med. Chem (1997) 5:1411
  • compound (VI) is a Neuropeptide Y receptor ligand described in Bioorg. Med. Chem, (1999) 7:1703.
  • Dimethylthiofoxins are analagous to the Thiofoxins, except that penicillamine is used in place of cysteine. Dimethylthiofoxins are then products of the coupling of penicillamine with a ⁇ -amino alcohol (possibly derived from the reduction of an ⁇ -amino acid).
  • the R 1 group is introduced, then the R 3 /R 4 group, and then the compounds are cyclised. Such a route would be optimal if greater diversity was to be introduced at R 3 /R 4 than R 1 .
  • the R 1 -containing acyl (or sulfonamide) substituent is introduced onto pencillamine by an appropriate amide coupling route, several of which are well known in the art, e.g. DCC coupling.
  • one or more ⁇ -amino alcohols are obtained (e.g. ephedrine) or synthesised from ⁇ -amino acids,
  • the amino agroup is protected (e.g. by addition of a Boc group, or by obtaining the appropriately protected ⁇ -amino acid from a commercial supplier).
  • Boc-protected amino acids are converted to amino alcohols by reduction, and the Boc-protected ⁇ -amino alcohol (whether purchased or obtained by reduction of an amino acid) is mesylated.
  • suitable methods for reduction and mesylation exist, and are well known in the art (e.g. Synthesis (1992) 1359 or Synthesis (1996) 1223).
  • the acylpenicillamine is alklylated at the sulfur centre using any of several appropriate methods which are well known in the art (e.g. J Med Chem. (1987) 30:1984).
  • Each ⁇ -amino alcohol is reacted separately with an appropriate acylpenicillamine to yield individual library elements with variable R 1 , R 2 and R 3 depending on the selection of acylcysteines and ⁇ -amino alcohols available.
  • the nitrogen introduced at this step is hereafter termed the ⁇ -nitrogen.
  • the S-alkyl acylpencillamines are cyclised.
  • the ⁇ -amine is selectively deprotected and condensed with the carboxy ester (or after selective hydrolysis the corresponding carboxylic acid) to form a seven-membered ring, yielding Dimethylthiofoxin library elements. Similar methods are well known in the art (e.g. J. Med. Chem (1987) 30:1984).
  • penicillamine is selectively protected at the ⁇ -amine, and is then alkylated on S with an N-protected ⁇ -amino-alcohol in which the alcohol has been activated to form a leaving group suitable for nucleophilic substitution with inversion of stereochemistry at carbon.
  • the introduced nitrogen is here-on called the ⁇ -amine group (for similar see Tetrahedron, 1999, 55, 10155).
  • One or more ⁇ -amino alcohols suitable for this alkylation are obtained (e.g. ephedrine) or synthesised from ⁇ -amino acids, In each case, the amino agroup is protected (e.g. by addition of a Boc group, or by obtaining the appropriately protected ⁇ -amino acid from a commercial supplier). Boc-protected amino acids are converted to amino alcohols by reduction, and the Boc-protected ⁇ -amino alcohol (whether purchased or obtained by reduction of an amino acid) is mesylated.
  • Several suitable methods for reduction and mesylation exist, and are well known in the art (e.g. Synthesis (1992) 1359 or Synthesis (1996) 1223).
  • the ⁇ -amine is selectively deprotected and condensed with the carboxy ester (or after selective hydrolysis the corresponding carboxylic acid) to form a seven-membered ring (according to J. Med. Chem., 1987, 30, 1984).
  • the ⁇ -amine is selectively deprotected and acylated as required to introduce diversity at the R 1 position, using an appropriate peptide coupling reagent, several of which are well known in the art.
  • the Azafoxins are the products of the coupling of 3-aminoalanine with a ⁇ -amino alcohol (possibly derived from the reduction of an ⁇ -amino acid).
  • the introduction of a further nitrogen into the lactam ring in Azafoxins allows for the possibility of further substitution (and hence diversity) at the ring heteroatom.
  • the R 1 group is introduced, then the R 2 group (substitution at nitrogen) and then the R 3 /R 4 group, before finally the compounds are cyclised.
  • Such a route would be optimal if greater diversity was to be introduced at R 3 /R 4 than R 2 with least diversity at R 1 .
  • a protected 3-aminoalanine is synthesised, for example by the Hoffman degradation of N- ⁇ -carbamate ester protected asparagine (according to J. Org. Chem., 1997 , 62 , 6918 ), and the carboxylic acid is esterified ((according to J. Med. Chem., 1998, 41, 2786).
  • the free ⁇ -amine is then orthogonally protected and the ⁇ -amine selectively deprotected by removal of the carbamate ester.
  • the free ⁇ -amine is then acylated as in the previous examples to introduce the R 1 functionality.
  • R 2 functionality is introduced, for example by mono-alkylation, mono-arylation or reductive alkylation, or by acylation with sulfonyl chloride, using reaction conditions well known in the literature.
  • the ⁇ -amine is then alkylated with an N-protected ⁇ -amino-alcohol in which the alcohol has been activated to form a leaving group suitable for nucleophilic substitution with inversion of stereochemistry at carbon (as described for Thiofoxins and Dimethylthiofoxins).
  • the ⁇ -amine can be condensed with an N-protected ⁇ -amino-aldehyde in the presence of a reducing agent forming an amine (according to J. Org. Chem., 2002, 67, 4017).
  • the introduced nitrogen is here-on called the ⁇ -amine group.
  • This step introduces the R 3 /R 4 functionality, depending on the selected ⁇ -aminoalcohol (possibly derived from an ⁇ -amino acid).
  • the ⁇ -amine is selectively deprotected and condensed with the carboxy ester (or after selective hydrolysis the corresponding carboxylic acid) to form a seven-membered ring (according to J. Med. Chem., 1987, 30, 1984).
  • protected 3-aminoalanine is synthesised, for example by Hoffman degradation of N- ⁇ -protected asparagine, and is then orthogonally protected on the ⁇ -amine, deprotected and acylated at the ⁇ -amine and esterified at the carboxylic acid all as described for Scheme 3A.
  • the ⁇ -amine is alkylated on nitrogen with an N-protected ⁇ -amino-alcohol in which the alcohol has been activated to form a leaving group suitable for nucleophilic substitution with inversion of stereochemistry at carbon (as described for Thiofoxins and Dimethylthiofoxins).
  • the ⁇ -amine can be condensed with an N-protected ⁇ -amino-aldehyde in the presence of a reducing agent forming an amine (according to J. Org. Chem., 2002, 67, 4017).
  • the introduced nitrogen is here-on called the ⁇ -amine group.
  • This step introduces the R 3 /R 4 functionality, depending on the selected ⁇ -aminoalcohol (possibly derived from an ⁇ -amino acid).
  • the ⁇ -amine is then selectively deprotected and condensed with the carboxy ester (or after selective hydrolysis the corresponding carboxylic acid) to form a seven-membered ring (according to J. Med. Chem., 1987, 30, 1984).
  • R 2 functionality is introduced, for example by mono-alkylation, mono-arylation or reductive alkylation, or by acylation with sulfonyl chloride, using reaction conditions well known in the literature.
  • the R 2 group is introduced, then the R 1 group and then the R 3 /R 4 group(s), before the compounds are finally cyclised.
  • Such a route would be optimal if greater diversity was to be introduced at R 3 /R 4 than R 1 with least diversity at R 2 .
  • protected 3-aminoalanine is synthesised, for example by Hoffman degradation of N- ⁇ -protected asparagine, and the carboxylic acid esterified (as in Scheme 3A, for example), but the ⁇ -amine is then mono-alkylated, mono-arylated or sulfonated as required to introduce the R 2 functionality, using methods well known in the literature. Thereafter, the secondary ⁇ -amine is protected orthogonally to the ⁇ -amine.
  • the ⁇ -amine is selectively deprotected and acylated as described above to introduce the R 1 functionality.
  • the ⁇ -amine is alkylated on nitrogen with an N-protected ⁇ -amino-alcohol in which the alcohol has been activated to form a leaving group suitable for nucleophilic substitution with inversion of stereochemistry at carbon (as described for Thiofoxins and Dimethylthiofoxins).
  • the ⁇ -amine can be condensed with an N-protected ⁇ -amino-aldehyde in the presence of a reducing agent forming an amine (according to J. Org. Chem., 2002, 67, 4017).
  • the introduced nitrogen is here-on called the ⁇ -amine group.
  • This step introduces the R 3 /R 4 functionality, depending on the selected ⁇ -aminoalcohol (possibly derived from an ⁇ -amino acid).
  • the ⁇ -amine is then selectively deprotected and condensed with the carboxy ester (or after selective hydrolysis the corresponding carboxylic acid) to form a seven-membered ring (according to J. Med. Chem., 1987, 30, 1984).
  • the R 2 group is introduced, then the R 3 /R 4 group(s).
  • the compounds are next cyclised, and finally the R 1 group is introduced.
  • Such a route would be optimal if greater diversity was to be introduced at R 1 than R 3 /R 4 with least diversity at R 2 .
  • protected 3-aminoalanine is synthesised, for example by Hoffman degradation of N- ⁇ -protected asparagine, and the carboxylic acid esterified.
  • the ⁇ -amine is then mono-alkylated, mono-arylated or sulfonated as required to introduce the R 2 functionality, using methods well known in the literature, all as in Scheme 3C.
  • the secondary ⁇ -amine is alkylated on nitrogen with an N-protected ⁇ -amino-alcohol in which the alcohol has been activated to form a leaving group suitable for nucleophilic substitution with inversion of stereochemistry at carbon (as described for Thiofoxins and Dimethylthiofoxins).
  • the ⁇ -amine can be condensed with an N-protected ⁇ -amino-aldehyde in the presence of a reducing agent forming an amine (according to J. Org. Chem., 2002, 67, 4017).
  • the introduced nitrogen is here-on called the ⁇ -amine group.
  • This step introduces the R 3 /R 4 functionality, depending on the selected ⁇ -aminoalcohol (possibly derived from an ⁇ -amino acid).
  • the ⁇ -amine is then selectively deprotected and condensed with the carboxy ester (or after selective hydrolysis the corresponding carboxylic acid) to form a seven-membered ring (according to J. Med. Chem., 1987, 30, 1984).
  • the R 3 /R 4 group(s) are introduced first, followed by cyclisation.
  • the R 1 group and then the R 2 group are then introduced.
  • Such a route would be optimal if greater diversity was to be introduced at R 2 than R 1 with least diversity at R 3 /R 4 .
  • protected 3-aminoalanine is synthesised, for example by Hoffman degradation of N- ⁇ -protected asparagine, and the carboxylic acid esterified.
  • the ⁇ -amine is alkylated on nitrogen with an N-protected ⁇ -amino-alcohol in which the alcohol has been activated to form a leaving group suitable for nucleophilic substitution with inversion of stereochemistry at carbon (as described for Thiofoxins and Dimethylthiofoxins).
  • the ⁇ -amine can be condensed with an N-protected ⁇ -amino-aldehyde in the presence of a reducing agent forming an amine (according to J. Org. Chem., 2002, 67, 4017).
  • the introduced nitrogen is here-on called the ⁇ -amine group.
  • This step introduces the R 3 /R 4 functionality, depending on the selected ⁇ -aminoalcohol (possibly derived from an ⁇ -amino acid).
  • the ⁇ -amine is then selectively deprotected and condensed with the carboxy ester (or after selective hydrolysis the corresponding carboxylic acid) to form a seven-membered ring (according to J. Med. Chem., 1987, 30, 1984).
  • the secondary ⁇ -amine (now in the ring) is subsequently protected orthogonally to the ⁇ -amine.
  • ⁇ -amine is selectively deprotected and acylated as described above to introduce the R 1 functionality.
  • ⁇ -amine is deprotected and mono-alkylated, mono-arylated or sulfonated as required to introduce the R 2 functionality, using methods well known in the literature.
  • the R 3 /R 4 group(s) are introduced first, followed by cyclisation.
  • the R 2 group and then the R 1 group are then introduced.
  • Such a route would be optimal if greater diversity was to be introduced at R 1 than R 2 with least diversity at R 3 /R 4 .
  • the ⁇ -amine is then deprotected and acylated as described above to introduce the R 1 functionality.
  • the Amidofoxins are products of the coupling of 3-aminoalanine with an ⁇ -amino acid (as opposed to the coupling of 3-aminoalanine with a ⁇ -amino alcohol, possibly derived from an ⁇ -amino acid, which yields Azafoxins as described above).
  • substitution at the ring heteroatom is possible (R 2 ) to introduce further diversity.
  • the R 1 group is introduced, followed by the R 2 group (substitution on nitrogen), then the R 3 group, followed by cyclisation.
  • Such a route would be optimal if greater diversity was to be introduced at R 3 than R 2 with least diversity at R 1 .
  • the first step is to synthesise a protected 3-amino alanine, for example by subjecting an N- ⁇ -carbamate ester protected asparagine to Hoffman degradation (according to J. Org. Chem., 1997, 62, 6918).
  • the carboxylic acid group is then esterified, and the ⁇ -amine group protected orthogonally to the ⁇ -amine group.
  • the ⁇ -amine is also selectively deprotected, and mono-alkylated or mono-arylated as required, using methods well known in the literature, in order to introduce the R 2 functionality.
  • the secondary ⁇ -amine is then acylated with an N-protected ⁇ -amino-acid.
  • the introduced nitrogen is here-on called the ⁇ -amine group. It will be obvious than any of a range of suitable peptide coupling methods, well known in the literature, could be used to perform this step. This introduces the R 3 functionality, depending on the selection of the ⁇ -amino acid used in the reaction.
  • the ⁇ -amine is selectively deprotected and condensed with the carboxy ester (or after selective hydrolysis the corresponding carboxylic acid) to form a seven-membered ring (for example, according to J. Med. Chem., 1987, 30, 1984).
  • the first step is to synthesise a protected 3-aminoalanine, for example by subjecting an N- ⁇ -carbamate ester protected asparagine to Hoffman degradation (according to J. Org. Chem., 1997, 62, 6918).
  • the carboxylic acid group is then esterified, but the ⁇ -amine is mono-alkylated or mono-arylated, using methods well known in the literature, prior to protecting the resulting secondary the ⁇ -amine group orthogonally to the ⁇ -amine. This introduces the R 2 functionality.
  • the ⁇ -amine is selectively deprotected and acylated as described above. This introduces the R 1 functionality.
  • the secondary ⁇ -amine is then selectively deprotected and acylated with an N-protected ⁇ -amino-acid.
  • the introduced nitrogen is here-on called the ⁇ -amine group. It will be obvious than any of a range of suitable peptide coupling methods, well known in the literature, could be used to perform this step. This introduces the R 3 functionality, depending on the selection of the ⁇ -amino acid used in the reaction.
  • the ⁇ -amine is selectively deprotected and condensed with the carboxy ester (or after selective hydrolysis the corresponding carboxylic acid) to form a seven-membered ring (for example, according to J. Med. Chem., 1987, 30, 1984).
  • the R 2 group is introduced, followed by the R 3 group. Following cyclisation, the R 1 group is then introduced. Such a route would be optimal if greater diversity was to be introduced at R 1 than R 3 with least diversity at R 2 .
  • the first step is to synthesise a protected 3-aminoalanine, for example by subjecting an N- ⁇ -carbamate ester protected asparagine to Hoffman degradation (according to J. Org. Chem., 1997, 62, 6918).
  • the carboxylic acid group is then esterified, and the ⁇ -amine is mono-alkylated or mono-arylated, using methods well known in the literature, introducing the R 2 functionality.
  • the secondary ⁇ -amine is then acylated with an N-protected ⁇ -amino-acid.
  • the introduced nitrogen is here-on called the ⁇ -amine group. It will be obvious than any of a range of suitable peptide coupling methods, well known in the literature, could be used to perform this step. This introduces the R 3 functionality, depending on the selection of the ⁇ -amino acid used in the reaction.
  • the ⁇ -amine is selectively deprotected and condensed with the carboxy ester (or after selective hydrolysis the corresponding carboxylic acid) to form a seven-membered ring (for example, according to J. Med. Chem., 1987, 30, 1984).
  • a compound of the invention can be tested for antagonist activity at a given GPCR by exposing the receptor to a labelled ligand under appropriate conditions for binding, in the absence and presence of various concentrations of the test compound. The amount of label associated with the receptor is then quantitated. If the test compound is able to compete with the labelled ligand for binding then the amount of label associated with the receptor will decrease with increasing concentration of the test compound. From the plot of ligand bound against test compound concentration it is possible to estimate the binding affinity of the test compound to the receptor.
  • a source of the GPCR of interest The sequence of every member of the GPCR superfamily from humans is now available from the human genome sequence. Such sequences can be cloned into a suitable vector and expressed in a suitable cell type (for example, Jurkat T cells which are already known to express virtually no endogenous GCPRs with the exception of the chemokine receptor CXCR4). After selection using an antibiotic appropriate to the vector used, stable cell lines expressing high levels of the chosen GPCR can be established.
  • a suitable cell type for example, Jurkat T cells which are already known to express virtually no endogenous GCPRs with the exception of the chemokine receptor CXCR4
  • Membrane fractions from cell lines expressing the chosen GPCR can be prepared using a range of methods well known in the art. For example, according to Kuo et al. (Proc. Natl. Acad. Sci. USA (1980) 77:7039), the cells may be resuspended in 25 mM HEPES buffer pH7.5 containing 0.25M sucrose, 2.5 mM MgCl 2 , 2.5 mM EGTA and 50 mM ⁇ -mercaptoethanol, as well as protease inhibitors such as PMSF and leupeptin and split open using a Dounce homogeniser.
  • the suspension is then subjected to centrifugation at 120 ⁇ g to pellet unbroken cells and large cellular fragments, and the supernatant containing small membrane fragments and cytosolic components is retained. This supernatant is then subjected to ultracentrifugation at 100,000 ⁇ g, producing a pellet of membrane fragments enriched in the chosen GPCR.
  • the pellet is resuspended in an appropriate binding buffer, and the total protein concentration determined using, for example, a commercially available protein assay such as Coomassie Plus (Pierce).
  • the membrane preparation can be adjusted in volume to yield a standardised total protein concentration, for example of 1 mg/ml.
  • the standardised preparation can be stored at ⁇ 85° C. in aliquots until required.
  • a labelled ligand with high affinity for the chosen GPCR Suitable ligands for most GPCRs are well known in the literature. Such ligands may be the natural ligand for the receptor (for example, dopamine) or it may be a pharmacological tool (such as domperidone).
  • a list of suitable ligands for a wide range of commonly investigated GPCRs is provided in Table 1, but it will be obvious to those skilled in the art that other suitable ligands exist for many of these receptors.
  • Ligands most useful for this purpose will have an affinity constant for binding to the chosen receptor of at least 1 ⁇ M, and preferably less than 100 nM, and more preferably less than 10 nM.
  • the ligand Once the ligand has been selected, it will likely be necessary to label to the ligand to that subsequently the amount bound to the chosen GPCR can be determined (although it may be possible to perform an assay without labelling the ligand, providing that a sensitive and accurate method of determining the amount of unbound ligand is available—for example it may be possible to use an ELISA assay to measure unbound ligand, and by inference calculate the amount of bound ligand).
  • Appropriate methods of labelling the ligand vary depending on the nature of the ligand: small molecules may be most readily labelled with a radionuclide such as 3 H, 14 C or 35 S; peptides may be most readily labelled with a co-synthetic biotin (and subsequently with labelled streptavidin), with fluorescent tags (such as fluorescein isothiocyanate) or with radionuclides (such as 125 I-iodination of tyrosine residues in the peptide); proteins may be most readily labelled with fluorescent tags (such as fluorescein isothiocyanate) or with radionuclides (such as 125 I-iodination of tyrosine residues in the protein).
  • a radionuclide such as 3 H, 14 C or 35 S
  • peptides may be most readily labelled with a co-synthetic biotin (and subsequently with labelled streptavidin), with fluorescent tags (such as fluorescein iso
  • the extent of the labelling (that is, the proportion of molecules in the sample bearing the label) must be sufficient that the amount of ligand binding to the receptor can be conclusively quantitated.
  • the membrane preparation is mixed with the radioligand at a concentration near to the affinity constant for the binding of the ligand to the chosen GPCR.
  • the compound of the invention is also added at various concentrations.
  • a positive control inhibitor is added (which may be a large excess of the same ligand as the radioligand but in the absence of the radionuclide tag).
  • three tubes would be prepared under each set of conditions. The tubes are then incubated, typically at between 4° C.
  • the membrane-bound receptor (plus any bound radioligand) can be separated from free radioligand in solution by filtration through filters (such as GF/C filters treated with 1% polyethyleneimine). The filters may then be air-dried and subjected to scintillation counting to determine the fraction of the radioligand added which is now bound to the receptor.
  • the compounds of invention may be subjected to screening using commercially available receptor screening procedures (for example, the services offered by Cerep, 128 Rue Danton, Paris, France). Such services readily identify members of a library, such as the library provided for in the invention, which modulate ligand binding to one or more GPCRs.
  • commercially available receptor screening procedures for example, the services offered by Cerep, 128 Rue Danton, Paris, France.
  • Such services readily identify members of a library, such as the library provided for in the invention, which modulate ligand binding to one or more GPCRs.
  • Compounds identified as modulating ligand binding to one or more GPCRs using the methods outlined above will usually be full antagonists. However, it is necessary to perform functional assay in order to confirm the antagonist properties of the compound. For example, depending on the GPCR and/or the ligand used certain second messenger signals will be stimulated (or inhibited) in order to transduce the signal that the ligand is present.
  • Cells may show and increase (or a decrease) in the cellular concentration of cyclic adenosie monophosphate (cAMP), various phosphorylated inositol-containing compounds (including I(1,4,5)P3 and I(1,3,5)P3), calcium ions, polyadenosine or other intracellular messengers known in the art, in response to presentation of the ligand.
  • cAMP cyclic adenosie monophosphate
  • various phosphorylated inositol-containing compounds including I(1,4,5)P3 and I(1,3,5)P3
  • calcium ions polyadenosine or other intracellular messengers known in the art
  • Full antagonists will abrogate the change in intracellular messengers caused by the natural ligand(s), and have no effect in the absence of natural ligand.
  • full agonists will have no effect when added with the natural ligand(s), but mimic the changes in intracellular messengers caused by the natural ligand(s) when added in the absence of natural lig
  • Some compounds may be partial antagonists, partial agonists or mixed agonist/anatgonists depending on the pattern of effects on intracellular messengers. Despite the complex pharmacological definition of such compounds, they may have useful therapeutic properties in certain diseases, and a number of well established human pharmaceuticals are known to be partial agonists, partial antagonists or mixed agonist/antagonists at one or more GPCRs.
  • the compounds of the invention are, therefore, likely to be particularly useful in the search for agonists than general lead discovery libraries because of the higher incidence of GPCR agonists among the library elements.
  • a test for a GPCR agonist requires a cell or organ culture system which responds to a natural ligand of the chosen GPCR(s) with a desirable biochemical or physiological response.
  • a response include, but are not limited to, changes in intracellular messengers (such as cAMP, IP(1,4,5)P3, calcium ions or polyadenosine), changes in enzyme activity (such as activation of protein kinases, phosphatases, metabolic enzymes or transport proteins), changes in gene expression patterns, altered phagocytosis, altered protein secretion, altered rate of proliferation, contraction of muscle cells/tissue, neurotransmission and so forth. Since responses such as these are inherently more complex to measure than the binding of natural ligand(s) to chosen GPCRs, this is why assays for GPCR agonists are more challenging than for antagonists.
  • a compound of the invention is an agonist at one or more chosen GPCRs.
  • Cells are exposed to various concentrations of the test compound, for example, by addition of the compound in a suitable vehicle (such as DMSO, ethanol or methanol) at various concentrations (for example, from about 0.1 nM to about 10 mM) in the cell culture medium for period of time (for example, from 1 minute to 48 hours, depending on the timecourse of the response to be measured), typically at 37° C.
  • a suitable vehicle such as DMSO, ethanol or methanol
  • concentrations for example, from about 0.1 nM to about 10 mM
  • period of time for example, from 1 minute to 48 hours, depending on the timecourse of the response to be measured
  • cells are also exposed to the natural ligand, and left unexposed to any additional compound(s) (as control cells).
  • a response known in the art to occur in response to the natural ligand binding to the chosen GPCR(s) is measured. If the compound of the invention is an agonist at the chosen GPCRs, then the responses to the test compound (at certain concentrations) will be qualitatively similar to the response to the natural ligand.
  • Somatostatin is an agonist at the sstr2 and sstr5 receptors such that it inhibits the secretion of growth hormone by isolated pituitary cells.
  • compounds of the invention are agonists at sstr2 and/or sstr5
  • rat pituitary cells are isolated and placed into culture. The cells are then incubated alone, or in the presence of somatostatin at 33 nM, or in the presence of the test compound(s) at various concentrations from about 0.1 nM to about 10 mM at 37° C. for 24 hours.
  • the cell culture medium is removed, clarified by centrifugation and subjected to an assay for growth hormone (GH), for example by performing a commercially available ELISA or radioimmunoassay.
  • GH growth hormone
  • the cells exposed to somatostatin will have produced between 30% and 90% less GH than cells incubated alone. If the compound of the invention is an agonist at the somatostatin receptors, then the level of GH will be lower in the medium from cells exposed to the test compound (at least at certain concentrations) than in the medium from cells incubated alone.
  • medium is collected from three replicate wells containing cells treated identically under each of the conditions of the experiment, so that an appropriate statistical test (such as an ANOVA or unpaired Student's t-test) can be used to demonstrate that the test compound produced a statistically significant reduction in GH secretion, and therefore likely possesses agonist activity at the chosen receptors, sstr2 and/or sstr5.
  • an appropriate statistical test such as an ANOVA or unpaired Student's t-test
  • Endothelin-1 is a peptide which signals through the ET-A and/or ET-B receptor to cause vasoconstriction.
  • rings of human aorta obtained from transplant donor hearts
  • Rings are then exposed either to increasing concentrations of Endothelin-1 (from 0.01 nM to 100 nM), or to increasing concentrations of the test compound(s) (from about 0.1 nM to about 10 mM) at 37° C., raising the concentration of the appropriate agent approximately every 5 minutes.
  • the contraction of the aortic ring is measured by a strain gauge designed and commercially available for such a purpose.
  • the rings exposed to endothelin-1 will contract as the concentration of endothelin-1 is increased, so that by the time the top concentration is reached the force exerted on the strain gauge will be significantly higher than prior to addition of endothelin-1. If the compound of the invention is an agonist at the endothelin receptors, then the force exerted on the strain gauge will also be higher (at least at certain concentrations) than prior to addition of the test compound.
  • aortic rings are treated with increasing concentrations of the same agent under identical experimental conditions, so that an appropriate statistical test (such as an ANOVA or unpaired Student's t-test) can be used to demonstrate that the test compound produced a statistically significant increase in aortic contraction, and therefore likely possesses agonist activity at the chosen receptors, ET-A and/or ET-B
  • the chemokine SDF-1a is a peptide which signals through the CXCR4 receptor to cause leukocyte migration.
  • CXCR4 cultured human immortalised T-cells Jurkat T cells, for example
  • Replicate wells are then exposed to lower chambers containing only culture medium, or to lower chambers containing SDF-1a at 75 nM, or to lower chambers containing various concentrations of the test compound(s) (from about 0.1 nM to about 10 mM) and incubated for a period of time (typically between 30 minutes and 3 hours) at 37° C.
  • the number of cells present in the lower chamber is a measure of the amount of migration occurring.
  • the number of cells in the lower chamber may be counted by direct visualisation, or by various well-known methods such as incubation with MTT dye which is converted to an insoluble blue formazan product in proportion to the number of cells present.
  • MTT dye which is converted to an insoluble blue formazan product in proportion to the number of cells present.
  • the number of cells in the lower chamber will be between 2-fold and 10-fold higher than the number of cells in lower chambers containing culture medium alone. If the compound of the invention is an agonist at CXCR4, then the number of cells in the lower chambers containing the test compound(s) will also be higher (at least at certain concentrations) than in the lower chambers containing medium alone.
  • test compound typically produced a statistically significant increase in leukocyte migration, and therefore likely possesses agonist activity at the chosen receptor, CXCR4.
  • the bioactive amine adrenalin increases the intracellular concentration of cAMP in vascular smooth muscle cells.
  • compounds of the invention are agonists at ⁇ -adrenoreceptors, rat vascular smooth muscle cells from thoracic aorta are isolated and placed into culture. The cells are then incubated alone, or in the presence of the adrenalin agonist salbutamol at 33 nM, or in the presence of the test compound(s) at various concentrations from about 0.1 nM to about 10 mM at 37° C. for 15 minutes.
  • the cell culture medium is removed, the cells are washed three times in cold buffer and then lysed in an appropriate lysis buffer, prior to measurement of the intracellular concentration of cAMP, for example by performing a commercially available ELISA or radioimmunoassay.
  • the cells exposed to salbutamol will have an intracellular cAMP concentration between 15% and 150% higher than cells exposed to medium alone. If the compound of the invention is an agonist at the ⁇ -adrenoreceptors, then the intracellular concentration of cAMP will be higher in the cells exposed to the test compound (at least at certain concentrations) than in the cells incubated alone.
  • cell lysate is prepared from three replicate wells containing cells treated identically under each of the conditions of the experiment, so that an appropriate statistical test (such as an ANOVA or unpaired Student's t-test) can be used to demonstrate that the test compound produced a statistically significant increase in intracellular cAMP concentration, and therefore likely possesses agonist activity at the chosen ⁇ -adrenoreceptors.
  • an appropriate statistical test such as an ANOVA or unpaired Student's t-test
  • a compound of the invention demonstrated to elevate cAMP in vascular smooth muscle cells to the same extent as the ⁇ -adrenoreceptor agonist salbutamol may be an agonist at the ⁇ -adrenoreceptor GPCRs, or it may be an agonist at another GPCR which also elevates cAMP (such as dopamine D2 receptor).
  • a compound of the invention which stimulates the migration of leukocytes to a similar extent to SDF-1a may be an agonist at CXCR4, or it may be an agonist at another GPCR which stimulates leukocyte migration (such as the C5a receptor).
  • Validation of the molecular target GPCR at which compounds of the invention act as an agonist will require the performance of additional experiments using specific antagonists already identified against the chosen GPCR, or the use of recombinant cell lines expressing only the chosen GPCR.
  • CXCR4 was the molecular target of the compound of the invention.
  • the leukocyte migration induced by a compound of the invention was observed using a cell line expressing CXCR4, but absent in the same cell line not expressing CXCR4, then it would be reasonable to conclude that CXCR4 was the molecular target of the compound of the invention.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
US11/815,928 2005-02-11 2006-02-10 Ligands for G-Protein Coupled Receptors Abandoned US20080261948A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0502914A GB2423085C (en) 2005-02-11 2005-02-11 Ligands for G-protein coupled receptors
GB0502914.5 2005-02-11
PCT/GB2006/000475 WO2006085096A1 (fr) 2005-02-11 2006-02-10 Ligands des récepteurs couplés aux protéines g

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2006/000475 A-371-Of-International WO2006085096A1 (fr) 2005-02-11 2006-02-10 Ligands des récepteurs couplés aux protéines g

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/289,542 Continuation US8618283B2 (en) 2005-02-11 2011-11-04 Ligand libraries for screening GPCRs

Publications (1)

Publication Number Publication Date
US20080261948A1 true US20080261948A1 (en) 2008-10-23

Family

ID=34356201

Family Applications (2)

Application Number Title Priority Date Filing Date
US11/815,928 Abandoned US20080261948A1 (en) 2005-02-11 2006-02-10 Ligands for G-Protein Coupled Receptors
US13/289,542 Expired - Fee Related US8618283B2 (en) 2005-02-11 2011-11-04 Ligand libraries for screening GPCRs

Family Applications After (1)

Application Number Title Priority Date Filing Date
US13/289,542 Expired - Fee Related US8618283B2 (en) 2005-02-11 2011-11-04 Ligand libraries for screening GPCRs

Country Status (9)

Country Link
US (2) US20080261948A1 (fr)
EP (2) EP2508515A1 (fr)
JP (1) JP2008530069A (fr)
CN (2) CN102161644A (fr)
AU (2) AU2006212016B2 (fr)
CA (1) CA2597481A1 (fr)
GB (1) GB2423085C (fr)
RU (1) RU2471022C2 (fr)
WO (1) WO2006085096A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8618283B2 (en) 2005-02-11 2013-12-31 Cambridge Enterprise Limited Ligand libraries for screening GPCRs
WO2021247978A1 (fr) * 2020-06-05 2021-12-09 The Rockefeller University Produits naturels bioinformatiques synthétiques antibactériens et leurs utilisations

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2452696B (en) 2007-08-02 2009-09-23 Cambridge Entpr Ltd 3-(2',2'-dimethylpropanoylamino)-tetrahydropyridin-2-one and its use in pharmaceutical compositions
US7662967B2 (en) 2007-08-02 2010-02-16 Cambridge Enterprise Limited Anti-inflammatory compounds and compositions
JP2012519272A (ja) * 2009-02-27 2012-08-23 ケンブリッジ エンタープライズ リミティド 改善された同定方法
MX2012007508A (es) * 2009-12-28 2012-08-01 Ajinotomo Co Inc Derivados de lantionina.
GB201009603D0 (en) 2010-06-08 2010-07-21 Cambridge Entpr Ltd Anti-inflammatory agent
TW202410918A (zh) * 2022-05-27 2024-03-16 韓商Ｄ＆Ｄ製藥科技股份有限公司 用於治療神經病症之組合物及方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4512988A (en) * 1984-03-01 1985-04-23 E. R. Squibb & Sons, Inc. Acylamino oxo or hydroxy substituted alkylamino thiazines and thiazepines
JPS61267579A (ja) * 1984-12-26 1986-11-27 Sankyo Co Ltd ４−アザ−５−オキソ−１−チアシクロヘプタン誘導体
JPH07113020B2 (ja) * 1985-09-12 1995-12-06 三共株式会社 ペルヒドロ―１，４―チアゼピン誘導体の製造法
US6664367B1 (en) * 1994-07-21 2003-12-16 Biosynthema, Inc. Stable analogs of bioactive peptides containing disulfide linkages
US7001899B2 (en) * 2002-06-10 2006-02-21 The Procter & Gamble Company Interleukin converting enzyme inhibitors
TW200502221A (en) * 2002-10-03 2005-01-16 Astrazeneca Ab Novel lactams and uses thereof
JO2355B1 (en) * 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
GB2423085C (en) 2005-02-11 2011-11-09 Cambridge Entpr Ltd Ligands for G-protein coupled receptors

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8618283B2 (en) 2005-02-11 2013-12-31 Cambridge Enterprise Limited Ligand libraries for screening GPCRs
WO2021247978A1 (fr) * 2020-06-05 2021-12-09 The Rockefeller University Produits naturels bioinformatiques synthétiques antibactériens et leurs utilisations

Also Published As

Publication number Publication date
AU2006212016B2 (en) 2012-02-23
WO2006085096A1 (fr) 2006-08-17
CA2597481A1 (fr) 2006-08-17
CN102161644A (zh) 2011-08-24
GB0502914D0 (en) 2005-03-16
RU2007130411A (ru) 2009-03-20
US8618283B2 (en) 2013-12-31
JP2008530069A (ja) 2008-08-07
EP1853569A1 (fr) 2007-11-14
GB2423085A (en) 2006-08-16
US20120046198A1 (en) 2012-02-23
CN101142196A (zh) 2008-03-12
AU2010227102A1 (en) 2010-11-04
AU2010227102B2 (en) 2011-12-22
RU2471022C2 (ru) 2012-12-27
GB2423085C (en) 2011-11-09
EP2508515A1 (fr) 2012-10-10
GB2423085B (en) 2010-05-26
AU2006212016A1 (en) 2006-08-17

Similar Documents

Publication Publication Date Title
US8618283B2 (en) Ligand libraries for screening GPCRs
US8389279B2 (en) α-aminocyclolactam ligands for G-protein coupled receptors, and methods of using same
US6313097B1 (en) Antagonists of calcitonin gene-related peptide
PL196641B1 (pl) Związki laktamowe i środek farmaceutyczny
CA2324474A1 (fr) Composes destines a inhiber la liberation et/ou la synthese du peptide beta-amyloide
EP0421802A2 (fr) 1,4-Benzodiazépines substituées en 3, utiles comme antagonistes d'oxytocine
US6638941B1 (en) Conformationallly constrained peptidomimetics as β-turn templates and modulators of SH3 domains
CA2547651A1 (fr) Agents anti-inflammatoires
AU2011226837B2 (en) Ligands for G-protein coupled receptors
GB2467060A (en) Dimethylthiofoxins and azafoxins which may be useful as ligands for G-protein coupled receptors
Grainger et al. Broad spectrum chemokine inhibitors related to NR58-3.14. 3
WO2004014425A1 (fr) Activateurs de canaux de potassium actives par calcium de conductance faible et utilisation associee
NZ236233A (en) 2-amide derivatives of 2-azabicyclo (2.2.2) octane- and (2.2.1) heptane-3-carboxylic acid derivatives with substituted amino acids
MXPA01007986A (en) Modified amino-acid amides as cgrp antagonists
AU2005228986A1 (en) Melanin-concentrating hormone receptor antagonists and methods of use

Legal Events

Date Code Title Description
AS Assignment

Owner name: HUNTSMAN TEXTILE EFFECTS (GERMANY) GMBH, TEXAS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CHROBACZEK, HARALD;ANGELE, THEODOR;DAUTH, JOCHEN;REEL/FRAME:019708/0375

Effective date: 20070502

AS Assignment

Owner name: CAMBRIDGE ENTERPRISE LIMITED, UNITED KINGDOM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GRAINGER, DAVID J.;FOX, DAVID JOHN;REEL/FRAME:022001/0401;SIGNING DATES FROM 20080102 TO 20080103

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION